PA-REPLY
1.8.2024 21:25:33 CEST | Business Wire | Press release
Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 30 June 2024.
Since the start of the year, the Group has recorded a consolidated turnover of €1,114.3 million, which is an increase of 7.3% compared to the same period in 2023.
All indicators are positive for the period. In the first half of 2024, consolidated EBITDA of €180.5 million compared to the €154.0 million recorded in 2023 and corresponds to 16.2% of turnover.
EBIT, from January to June, was €146.6 million (€123.7 million in 2023), corresponding to 13.2% of turnover.
Pre-tax profit, from January to June 2024, was €146.3 million (€113.6 million in 2023), corresponding to 13.1% of turnover.
As regards the second quarter 2024, the Group's performance was also positive, with consolidated turnover for the period of €560.0 million, up by 8.0% compared to 2023.
EBITDA, from April to June 2024, amounted to €93.2 million, with EBIT of €74.5 million and pre-tax profit of €73.2 million.
As at 30 June 2024, the Group's net financial position was positive for €234.8 million, while at 31 March 2024 was positive for €368.9 million. The financial position at 31 December 2023 was positive for €204.9 million.
“In the first half of 2024” - stated Mario Rizzante, Chairman of Reply - “we have experienced a positive trend, both in terms of revenue and profitability. These achievements were possible thanks to the leadership gained in the two main directions of technological transformation: artificial intelligence and cloud computing.”
“The strength of Reply” - continued Mario Rizzante - “has always been its ability to interpret innovation by making it relevant to the needs of companies. From this perspective, the first six months of 2024 were characterized by significant development in our main lines of offering. In particular, we witnessed a strong growth in demand from our customers for a new class of objects and services natively designed to integrate the most advanced artificial intelligence solutions onboard. This new way of interpreting artificial intelligence requires companies to pay great attention both in rethinking the underlying data models and in designing new architectures and conversational interfaces capable of fully exploiting its potential in complete security.”
“Being able to guide the growing spread of artificial intelligence” - concluded Mario Rizzante - “along with awareness of its potential and associated risks, is certainly the main challenge for the near future. In this scenario, Reply positions itself as a highly technological player capable of supporting its clients in creating the new digital economy.”
The Board of Directors of Reply has also approved the proposal to submit to the Extraordinary General Meeting of the Company, scheduled for September 17, 2024, on first call, the amendment of the Articles of Association, in order to allow, among other things, the enhancement of the increased voting system, in line with new legal provisions.
With the introduction of a reinforced increased voting mechanism, compared to the one already adopted, Reply intends to encourage a stable capital structure capable of supporting long-term growth in a highly competitive market.
The manager responsible for preparing the company's financial reports, Dr Giuseppe Veneziano, states in accordance with Paragraph 2 of Article 154-bis of the Consolidated Finance Act, that the accounting information contained in this press release corresponds to the company's records, ledgers and accounting entries.
Reply
Reply [EXM, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialised companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of AI, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com
This press release is a translation, the Italian version will prevail.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801271652/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom